Ketogenic diet effects on neurobehavioral development of children with intractable epilepsy: A prospective study

Dengna Zhu1, Mingmei Wang1, Jun Wang1

  • 1Cerebral Palsy Rehabil. Dept., Zhengzhou Univ., Affiliated Hosp 3, Zhengzhou 450052, Henan, PR China.

Epilepsy & Behavior : E&B
|January 17, 2016
PubMed

Insights

The ketogenic diet (KD) improves neurobehavioral development in children with intractable epilepsy. Early EEG changes predict treatment success, showing KD is safe and effective.

Area of Science:

  • Pediatric Neurology
  • Neurodevelopmental Disorders
  • Dietary Therapies

Background:

  • Intractable epilepsy in children poses significant challenges to neurodevelopment.
  • The ketogenic diet (KD) is a recognized therapy for drug-resistant epilepsy.
  • Understanding KD's impact on neurobehavioral development is crucial.

Purpose of the Study:

  • To assess the effect of the ketogenic diet (KD) on neurobehavioral development in children with intractable epilepsy.
  • To confirm the efficacy of KD in this patient population.
  • To explore the correlation between early electroencephalography (EEG) changes and treatment outcomes.

Main Methods:

  • 42 children with intractable epilepsy initiated the classic KD protocol.
  • Gesell developmental scales assessed neurobehavioral quotients (adaptability, motor skills, social interaction) at baseline and 18 months.
  • Seizure frequency reduction and 24-h video-EEG changes were monitored.

Main Results:

  • Significant improvements observed in adaptability, gross motor, and fine motor development quotients.
  • Seizure frequency reduction of ≥50% achieved by 69.0% of patients at 3 months, decreasing over time.
  • Reduced epileptiform discharges on EEG after 1 month correlated with 3-month seizure control.

Conclusions:

  • Ketogenic diet (KD) treatment is associated with improved neurobehavioral development in children with intractable epilepsy.
  • Prolonged KD treatment yields greater developmental benefits.
  • KD is a safe and effective epilepsy therapy, with early EEG changes indicating potential efficacy.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
328
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
943
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.0K